Targeting IGF-1R in the treatment of sarcomas: Past, present and future

Bulletin du Cancer

Volumn 96, Issue 7-8, 2009, Pages

  Su, Young Kim ^a   Wan, Xiaolin ^a   Helman, Lee J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical trials; IGF family; IGF 1R antibody; Mechanisms of resistance; Sarcomas

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMG 479; AVE 1642; BIIB 022; CCL 779; CP 751871; CYCLOPHOSPHAMIDE; DEFOROLIMUS; EVEROLIMUS; IMATINIB; IMC A 12; IRINOTECAN; MK 0646; R 1507; RAPAMYCIN; SCH 717454; SOMATOMEDIN C RECEPTOR; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TOPOTECAN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SOMATOMEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; DRUG RESEARCH; DRUG TARGETING; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; OSTEOSARCOMA; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SYNOVIAL SARCOMA; TREATMENT RESPONSE; ANIMAL; DRUG ANTAGONISM; DRUG RESISTANCE; FORECASTING; METABOLISM; MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FORECASTING; HUMANS; MICE; RECEPTOR, IGF TYPE 1; SARCOMA; SOMATOMEDINS;

EID: 69149097240     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0915     Document Type: Review

References (30)

1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004 ; 4 : 505-518
2. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003 ; 195 : 127-137 (Pubitemid 36588961)
3. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 2007 ; 17 : 54-57 (Pubitemid 46299992)
4. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003 ; 63 : 4384-4388 (Pubitemid 36951007)
5. Bach LA, Headey SJ, Norton RS. IGF-binding proteins: the pieces are falling into place. Trends Endocrinol Metab 2005 ; 16 : 228-234
6. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-1 receptors in human cancer. Curr Pharm Des 2007 ; 13 : 671-686 (Pubitemid 46510744)
7. Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D. Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 1998 ; 121 : 19-26. (Pubitemid 28561545)
8. Scotlandi K, Benini S, Sarti M, Serra M, Lollini PL, Maurici D, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996 ; 56 : 4570-4574 (Pubitemid 26338048)
9. El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J Clin Invest 1991 ; 87 : 648-657
10. Chao W, D'Amore PA. IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 2008 ; 19 : 111-120
11. Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995 ; 11 : 2503-2507 (Pubitemid 26023817)
12. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 2004 ; 24 : 7275-7283 (Pubitemid 39014452)
13. Toretsky JA, Steinberg SM, Thakar M, Counts D, Pironis B, Parente C, et al. Insulin-like growth factor type I (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001 ; 92 : 2941-2947
14. Werner H, Shen-Orr Z, Rauscher FJ, Morris JF, Roberts CT, LeRoith D. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 1995 ; 15 : 3516-3522
15. Sun Y, Gao D, Liu Y, Huang J, Lessnick S, Tanaka S. IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1. Oncogene 2006 ; 25 : 1042-1052 (Pubitemid 43277012)
16. Benini S, Manara MC, Cerisano V, Perdichizzi S, Strammiello R, Serra M, et al. Contribution of MEK/MAPK and PI3-K signalling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int J Cancer 2004 ; 108 : 358-366 (Pubitemid 37549600)
17. Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998 ; 58 : 4127-4131 (Pubitemid 28440569)
18. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 2008 ; 50 : 1190-1197 (Pubitemid 351555543)
19. Martins AS, Mackintosh C, Martin DH, Campos M, Hernandez T, Ordonez JL, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006 ; 12 : 3532-3540 (Pubitemid 43910901)
20. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007 ; 12 : 1007-1018
21. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signalling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 2000 ; 14 : 783-794 (Pubitemid 32260492)
22. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of AKT signalling through an IGF-1R-dependent mechanism. Oncogene 2007 ; 26 : 1932-1940 (Pubitemid 46474636)
23. Cao L, Yu Y, Darko I, Currier D, Mayeenuddin LH, Wan X, et al. Addiction to elevated insulin-like growth factor 1 receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008 ; 68 : 8039-8048
24. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN task force report: management of patients with gastrointestinal stromal tumor (GIST) - update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007 ; 5 : s1-31. (Pubitemid 47067464)
25. Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, et al. Pediatric KIT-wild type and platelet-derived growth factor a wild type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res 2007 ; 67 : 9084-9088
26. Agaram NP, Laquaglia MP, Ustun B, Guo T, Wong GC, Socci ND, et al. Molecular characterization of pediatric gastrointestinal stromal tumors. Clin Cancer Res 2008 ; 14 : 3204-3215
27. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008 ; 105 : 8387-8392 (Pubitemid 351904765)
28. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol 2008 ; 19 : 1293-1298
29. Feng Y, Dimitrov DS. Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Dev 2008 ; 11 : 178-185 (Pubitemid 351281057)
30. Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa®) in human breast and prostate cancer cells. Endocr Relat Cancer 2004 ; 11 : 793-814. (Pubitemid 40065552)